Extracorporeal Treatments in Patients with Acute Kidney Injury and Sepsis.
Acute kidney injury (AKI) is one of the most common sepsis complications, and AKI development increases the risk of sepsis episodes by affecting host immune competence. The concomitance of these 2 clinical syndromes is associated with an extremely poor prognosis with mortality rates ranging from 50 to 70%. These unacceptable outcomes reflect the poor knowledge of the underlying pathogenic mechanisms and the lack of appropriate diagnostic and therapeutic methodologies as well as of appropriate experimental models. However, in recent years new insights have revolutionized the scientific and clinical approach to sepsis-induced AKI (S-AKI) leading to encouraging results. The aim of this paper is to review the extracorporeal treatment of S-AKI with a focus on the most promising experimental techniques and the underlying molecular mechanisms.